

Francesco Marchesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/647451/publications.pdf>

Version: 2024-02-01

124
papers

2,933
citations

279487

23
h-index

205818

48
g-index

126
all docs

126
docs citations

126
times ranked

4657
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	1.7	15
2	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	2.9	23
3	The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2. <i>British Journal of Haematology</i> , 2022, 196, 362-367.	1.2	15
4	Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. <i>Leukemia</i> , 2022, 36, 588-590.	3.3	23
5	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
6	Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016 survey. <i>Mycoses</i> , 2022, 65, 171-177.	1.8	3
7	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
8	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	0.6	70
9	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
10	In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1776.	1.0	1
11	A High-Risk Profile for Invasive Fungal Infections Is Associated with Altered Nasal Microbiota and Niche Determinants. <i>Infection and Immunity</i> , 2022, 90, e0004822.	1.0	6
12	CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. <i>Leukemia</i> , 2022, , .	3.3	2
13	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
14	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
15	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	1.5	0
16	Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	39
17	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	8
18	Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?. <i>Blood Reviews</i> , 2021, 47, 100776.	2.8	8

#	ARTICLE	IF	CITATIONS
19	Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. <i>British Journal of Haematology</i> , 2021, 193, 316-324.	1.2	12
20	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	2.0	4
21	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52.	0.8	10
22	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. <i>Journal of Hematology and Oncology</i> , 2021, 14, 81.	6.9	149
23	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. <i>HemaSphere</i> , 2021, 5, e612.	1.2	29
24	Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 119.	6.9	35
25	Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic Patients. <i>Infection and Immunity</i> , 2021, 89, e0010521.	1.0	12
26	Mir-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients. <i>British Journal of Haematology</i> , 2021, 195, 399-404.	1.2	5
27	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
28	The Impact of Bacterial Biofilms on End-Organ Disease and Mortality in Patients with Hematologic Malignancies Developing a Bloodstream Infection. <i>Microbiology Spectrum</i> , 2021, 9, e0055021.	1.2	21
29	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
30	Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin. <i>Blood</i> , 2021, 138, 4381-4381.	0.6	1
31	COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A) <i>Tj ETQq1 1 0.784314rgBT /Ov</i>		
32	Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT. <i>Transplant Infectious Disease</i> , 2021, , .	0.7	2
33	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
34	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. <i>Blood Cancer Journal</i> , 2020, 10, 85.	2.8	9
35	Ceftolozane-Tazobactam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020065.	0.5	2
36	Biofilm Production by Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Significantly Increases the Risk of Death in Oncological Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 561741.	1.8	30

#	ARTICLE	IF	CITATIONS
37	BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2020, 61, 2238-2241.	0.6	6
38	Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. <i>Mycoses</i> , 2020, 63, 900-910.	1.8	10
39	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 36.	1.5	15
40	Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3002-3005.	0.6	4
41	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1113-1118.	2.0	3
42	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <i>Annals of Hematology</i> , 2020, 99, 867-875.	0.8	8
43	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Chemotherapy</i> , 2020, 65, 35-41.	0.8	1
44	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
45	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	0.6	1
46	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. <i>Haematologica</i> , 2019, 104, 82-92.	1.7	24
47	Efficacy and safety of low dose ponatinib in a case of Ph ⁺ positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e15-e17.	1.2	7
48	Factors influencing the perception of protective isolation in patients undergoing haematopoietic stem cell transplantation: A multicentre prospective study. <i>European Journal of Cancer Care</i> , 2019, 28, e13148.	0.7	7
49	A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group. <i>American Journal of Hematology</i> , 2019, 94, 1104-1112.	2.0	19
50	The neutrophil/lymphocyte ratio ≥ 3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network "Rete Ematologica del Lazio per i Linfomi" (RELLI). <i>Leukemia and Lymphoma</i> , 2019, 60, 3386-3394.	0.6	11
51	Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , 2019, 14, e0224465.	1.1	27
52	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 197-205.	1.3	13
53	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1373.	1.8	15
54	Fungaemia in haematological malignancies: SEIFEM 2015 survey. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13083.	1.7	20

#	ARTICLE	IF	CITATIONS
55	The Effect of Docosahexaenoic Acid and Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541988858.	0.8	7
56	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. <i>Clinical Neuropharmacology</i> , 2019, 42, 167-171.	0.2	2
57	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. <i>Supportive Care in Cancer</i> , 2019, 27, 793-803.	1.0	8
58	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	1.3	11
59	Development and initial validation of a questionnaire to assess patients' perception of protective isolation following haematopoietic stem cell transplantation. <i>European Journal of Cancer Care</i> , 2019, 28, e12955.	0.7	7
60	Protection during haemopoietic stem cell transplantation: a survey from the quality of life working party of the Rome Transplant Network. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, 110-111.	0.8	2
61	Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. <i>HemaSphere</i> , 2019, 3, e320.	1.2	8
62	PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY. <i>HemaSphere</i> , 2019, 3, 580-581.	1.2	1
63	S1637 A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP. <i>HemaSphere</i> , 2019, 3, 756-757.	1.2	0
64	Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML. <i>Blood</i> , 2019, 134, 1458-1458.	0.6	1
65	Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. <i>Transfusion</i> , 2018, 58, 1143-1148.	0.8	4
66	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1051-1054.	1.3	4
67	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. <i>Chemotherapy</i> , 2018, 63, 55-63.	0.8	23
68	Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 161-162.	0.2	2
69	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. <i>Expert Review of Hematology</i> , 2018, 11, 155-168.	1.0	4
70	Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. <i>Annals of Hematology</i> , 2018, 97, 1717-1726.	0.8	72
71	Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. <i>Hematological Oncology</i> , 2018, 36, 381-391.	0.8	50
72	Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?. <i>Medical Mycology</i> , 2018, 56, 263-278.	0.3	3

#	ARTICLE	IF	CITATIONS
73	Gender, age and diagnosis effect on self-perceived pain in hematological patients: retrospective analysis of two case series. <i>Annals of Palliative Medicine</i> , 2018, 7, 484-486.	0.5	0
74	Isavuconazole: Case Report and Pharmacokinetic Considerations. <i>Chemotherapy</i> , 2018, 63, 253-256.	0.8	8
75	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 518-527.	1.3	4
76	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α -Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integrative Cancer Therapies</i> , 2018, 17, 1115-1124.	0.8	23
77	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 95.	3.5	25
78	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 158-168.	1.3	10
79	Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017. <i>Blood</i> , 2018, 132, 4164-4164.	0.6	4
80	Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study. <i>Blood</i> , 2018, 132, 3710-3710.	0.6	1
81	The predictive value of <i>Aspergillus</i> PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2943-2946.	0.6	6
82	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , 2017, 102, e407-e410.	1.7	17
83	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2017, 52, 154-156.	1.3	27
84	Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. <i>Chemotherapy</i> , 2017, 62, 58-61.	0.8	15
85	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	2.8	98
86	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	2.9	103
87	The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study. <i>Functional Neurology</i> , 2017, 32, 195.	1.3	4
88	<i>Campylobacter jejuni</i> Fatal Sepsis in a Patient with Non-Hodgkin's Lymphoma: Case Report and Literature Review of a Difficult Diagnosis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 544.	1.8	11
89	Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry. <i>Supportive Care in Cancer</i> , 2016, 24, 3839-3845.	1.0	16
90	Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 128.	3.5	16

#	ARTICLE	IF	CITATIONS
91	Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. <i>British Journal of Haematology</i> , 2016, 172, 980-982.	1.2	11
92	Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy?. <i>Cancer</i> , 2016, 122, 1461-1462.	2.0	2
93	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 49.	3.5	4
94	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. <i>Journal of Infection</i> , 2016, 72, 265-268.	1.7	17
95	Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia. <i>Cognitive Neurodynamics</i> , 2016, 10, 185-188.	2.3	2
96	Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. <i>Bone Marrow Transplantation</i> , 2016, 51, 638-639.	1.3	0
97	Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 489-492.	0.6	8
98	Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery. <i>Current Medicinal Chemistry</i> , 2016, 23, 2217-2229.	1.2	12
99	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , 2016, 128, 3700-3700.	0.6	0
100	Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. <i>World Journal of Transplantation</i> , 2015, 5, 129.	0.6	22
101	Comparison between biosimilar filgrastim vs other granulocyte colony stimulating factor formulations (originator filgrastim, pegfilgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. <i>British Journal of Haematology</i> , 2015, 169, 293-296.	1.2	10
102	Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 17.	2.0	7
103	High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 110-112.	0.8	82
104	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
105	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , 2015, 126, 1023-1023.	0.6	0
106	Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2004-2004.	0.6	0
107	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. <i>Blood</i> , 2015, 126, 4887-4887.	0.6	1
108	High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network. <i>Transplant Infectious Disease</i> , 2014, 16, 158-164.	0.7	38

#	ARTICLE	IF	CITATIONS
109	Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single institution study. <i>Transplant Infectious Disease</i> , 2014, 16, 1032-1038.	0.7	17
110	A Case of Transplantation-Associated Thrombotic Microangiopathy with Cardiac Involvement Successfully Treated with Plasma Exchange. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 369-371.	0.3	3
111	Survival of Patients with High Risk Hematological Malignancy after Allogeneic Transplant from HLA Identical Siblings Is Comparable to That of Patients Transplanted from Haploidentical, Unmanipulated Bone Marrow Donor: Results of a Matched-Pair Analysis from the Rome Transplant Network. <i>Blood</i> , 2014, 124, 1223-1223.	0.6	0
112	A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2013, 4, 242-248.	0.5	32
113	Triazene Compounds in the Treatment of Acute Myeloid Leukemia: A Short Review and a Case Report. <i>Current Medicinal Chemistry</i> , 2013, 20, 2389-2401.	1.2	17
114	Tuberculous Meningoencephalitis in a Patient with Hairy Cell Leukemia in Complete Remission. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2012, 52, 31-34.	0.3	6
115	The potential role of pretransplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. <i>American Journal of Hematology</i> , 2012, 87, 213-217.	2.0	14
116	Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: A concise review. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 331-346.	2.0	23
117	Systemic strongyloidiasis and primary aspergillosis of digestive tract in a patient with T-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 978-980.	0.4	1
118	Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/i>MLL-AF4</i>Positive B-Cell Acute Lymphoblastic Leukemia. <i>Advances in Hematology</i> , 2011, 2011, 1-8.	0.6	26
119	Hematologic Issues in Cervical Spine Surgery. , 2010, , 13-27.		0
120	Relapse of IgA λ Multiple Myeloma Presenting as Obstructive Jaundice and Abdominal Pain. <i>Oncology Research and Treatment</i> , 2009, 32, 119-121.	0.8	6
121	A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. <i>Annals of Hematology</i> , 2009, 88, 491-493.	0.8	13
122	Fibrin glue for endoscopic gastrointestinal bleeding in patients with impaired haemostasis. <i>Transfusion Medicine</i> , 2008, 18, 207-208.	0.5	2
123	Triazene compounds: Mechanism of action and related DNA repair systems. <i>Pharmacological Research</i> , 2007, 56, 275-287.	3.1	247
124	Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. <i>DNA Repair</i> , 2007, 6, 1179-1186.	1.3	18